Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the virtual SVB Securities Global Biopharma Conference taking place from February 14-16, 2023.
| Company Fireside Chat Presentation Details: | |
| Date: | Wednesday, February 15, 2023 |
| Time: | 3:00 pm Eastern Time (12:00 pm Pacific Time) |
| Presenters: | Ian Mortimer, President and CEO |
| Sherry Aulin, CFO | |
| Webcast: | Link to pre-register for the webcast can be . |
A live webcast of the company presentation will be available on the “” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email:
